Hyperparathyroidism is a relatively rare condition, affecting approximately 1 in 1,000 individuals. It is more common in women, especially postmenopausal women, with a female-to-male ratio of about 3:1. The prevalence increases with age, with the majority of cases occurring in individuals over 50 years old. Although the exact cause is unknown, certain factors like radiation exposure, certain genetic conditions, and family history may increase the risk. Early diagnosis and treatment are crucial to prevent complications associated with elevated levels of parathyroid hormone.
Hyperparathyroidism is a relatively rare endocrine disorder characterized by excessive production of parathyroid hormone (PTH) by the parathyroid glands. It affects the regulation of calcium and phosphorus levels in the body. The prevalence of hyperparathyroidism varies depending on the population studied and the diagnostic criteria used.
In the general population: The estimated prevalence of primary hyperparathyroidism, the most common form, is approximately 0.1% to 0.3%. It is more common in women, with a female-to-male ratio of about 3:1. The incidence increases with age, peaking in the 50s and 60s.
In certain high-risk groups: Hyperparathyroidism is more prevalent in individuals with certain conditions such as multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric hypercalcemia (FHH), and renal failure. In these populations, the prevalence can be significantly higher.
Diagnosis and treatment: Hyperparathyroidism is often diagnosed through blood tests that measure calcium and PTH levels. Treatment options include observation, medication, or surgical removal of the affected parathyroid glands.
While hyperparathyroidism is not a common condition, it is important to recognize its symptoms and seek medical attention for proper diagnosis and management.